Cardiff Oncology, Inc. (CRDF) News
Filter CRDF News Items
CRDF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CRDF News From Around the Web
Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-quarter ended March 31, 2023, and provided a business update. |
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal CancerCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that the first patient was dosed this month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The trial is designed to demonstrate a clinically meaningful difference in response and onvansertib's contribution to standard of care (SoC) FOLFIRI/bevac |
Cardiff Oncology Formally Introduces Scientific Advisory BoardCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today formally introduced the full membership of its Scientific Advisory Board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who bring depth and breadth of knowledge in oncology drug development, clinical trial design, translational science and clinical researc |
Cardiff Oncology Full Year 2022 Earnings: Beats ExpectationsCardiff Oncology ( NASDAQ:CRDF ) Full Year 2022 Results Key Financial Results Net loss: US$38.7m (loss widened by 37... |
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. |
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will participate in a corporate panel discussion and 1x1 investor meetings at the Cowen 43rd Annual Health Care Conference, which is taking place at the Boston Marriott Copley Place from March 6 – 8, 2023. |
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical OfficerCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer (CMO). Dr. Kabbinavar will oversee the clinical development program for the Company's investigational drug onvansertib and will report directly to Chief Executiv |
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023. |
Cardiff Oncology to Present at Upcoming Investor ConferencesCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference and the JMP Securities Hematology and Oncology Summit taking place on November 29 – December 1, 2022, and December 6 – 7, 2022, respectively. |
Cardiff Oncology to Present at the Jefferies London Healthcare ConferenceCardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London, UK from November 15 – 17, 2022. |